



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-002664-10/ Novartis Protocol ID CNVA237B2301

A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma

Trial CNVA237B2301 was cancelled with no patient enrollment and as such, no results will be reported.